| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2.13 MB | Adobe PDF |
Authors
Abstract(s)
Introdução: A aplicação da Toxina Botulínica (TB) no tratamento dos pacientes com
Distúrbios Temporomandibulares (DTM) é pouco estudada. Assim, o objetivo
fundamental desta revisão sistemática é procurar evidência científica que valide a
utilização da TB no tratamento de DTM.
Materiais e Métodos: A seleção dos estudos a incluir nesta revisão sistemática foi
realizada por 2 investigadores independentes de acordo com as normas PRISMA, a
questão de investigação pelo acrónimo PICO, e o protocolo de investigação registado
no PROSPERO (nºCRD42023388330). A pesquisa incidiu em 3 bases de dados:
PubMed/MEDLINE®, Web of Science® e Cochrane®. A qualidade dos estudos foi
aferida através da checklist de Downs and Black e a concordância entre examinadores
através do coeficiente de Kappa de Cohen. Recolheram-se dados referentes à data
de realização dos estudos, à população envolvida (idade, género, tamanho da
amostra), à marca de toxina utilizada, dosagem e locais de aplicação. Os principais
resultados e as principais conclusões de cada estudo incluído nesta revisão foram
analisados de forma comparativa.
Resultados: Através da pesquisa nas bases de dados referidas, obtiveram se 84
artigos. Após exclusão de duplicados/triplicados obtiveram-se 76 artigos. Dos 76
foram selecionados através da leitura do título (59 artigos), leitura do resumo (36
artigos) e por fim pela leitura do artigo completo chegou-se a um total de 17 artigos
incluídos para esta revisão. Foram utilizadas 3 marcas diferentes de TBA (BOTOXc
Allergan®, Dysport® IPSEN, Xeomeen® MERZ) com uma média de concentração de
100U diluídas numa solução salina. A principal indicação para a aplicação de TB é
patologia muscular e os locais preferenciais de infiltração são os músculos temporal e
masséter.
Conclusão: De um modo geral os estudos permitem concluir que o uso da toxina
botulínica demonstrou eficácia para o tratamento de DTM, no entanto continua a ser
um tratamento de segunda opção.
Introduction: The application of Botulinum Toxin (BT) in the treatment of patients with Temporomandibular Disorders (TMD) has been poorly studied. Therefore, the primary objective of this systematic review is to seek scientific evidence validating the use of BT in the treatment of TMD. Materials and Methods: The selection of studies to be included in this systematic review was conducted by 2 independent investigators according to PRISMA guidelines, the research question by the PICO acronym, and the research protocol registered in PROSPERO (CRD42023388330). The search focused on 3 databases: PubMed/MEDLINE®, Web of Science®, and Cochrane®. The quality of the studies was assessed using the Downs and Black checklist, and the agreement between examiners was measured using Cohen's Kappa coefficient. Data were collected regarding the date of the studies, the population involved (age, gender, sample size), the brand of toxin used, dosage, and application sites. The main results and conclusions of each study included in this review were analyzed comparatively. Results: Through the search in the databases, 84 articles were obtained. After excluding duplicates/triplicates, 76 articles remained. Out of the 76, selection was made based on title reading (59 articles), abstract reading (36 articles), and finally, after reading the full article, a total of 17 articles were included for this review. Three different brands of BT (BOTOX® Allergan, Dysport® IPSEN, Xeomeen® MERZ) were used with an average concentration of 100U diluted in a saline solution. The main indication for BT application is muscular pathology, and the preferred infiltration sites are the temporal and masseter muscles. Conclusion: In general, the studies allow us to conclude that the use of botulinum toxin has shown efficacy in the treatment of TMD, however, it remains a second-line treatment option.
Introduction: The application of Botulinum Toxin (BT) in the treatment of patients with Temporomandibular Disorders (TMD) has been poorly studied. Therefore, the primary objective of this systematic review is to seek scientific evidence validating the use of BT in the treatment of TMD. Materials and Methods: The selection of studies to be included in this systematic review was conducted by 2 independent investigators according to PRISMA guidelines, the research question by the PICO acronym, and the research protocol registered in PROSPERO (CRD42023388330). The search focused on 3 databases: PubMed/MEDLINE®, Web of Science®, and Cochrane®. The quality of the studies was assessed using the Downs and Black checklist, and the agreement between examiners was measured using Cohen's Kappa coefficient. Data were collected regarding the date of the studies, the population involved (age, gender, sample size), the brand of toxin used, dosage, and application sites. The main results and conclusions of each study included in this review were analyzed comparatively. Results: Through the search in the databases, 84 articles were obtained. After excluding duplicates/triplicates, 76 articles remained. Out of the 76, selection was made based on title reading (59 articles), abstract reading (36 articles), and finally, after reading the full article, a total of 17 articles were included for this review. Three different brands of BT (BOTOX® Allergan, Dysport® IPSEN, Xeomeen® MERZ) were used with an average concentration of 100U diluted in a saline solution. The main indication for BT application is muscular pathology, and the preferred infiltration sites are the temporal and masseter muscles. Conclusion: In general, the studies allow us to conclude that the use of botulinum toxin has shown efficacy in the treatment of TMD, however, it remains a second-line treatment option.
Description
Keywords
Distúrbios temporomandibulares Toxina botulínica Articulação temporomandibular Revisão sistemática Temporomandibular disorders Botulinum toxin Temporomandibular joint Systematic review.